Abeomics

Abeomics is a privately held biotechnology company providing critical research reagents and custom services to accelerate drug discovery and biomedical research. The company leverages recombinant antibody technology to produce biosimilars of key therapeutic antibodies like Trastuzumab, alongside a broad portfolio of tools targeting pathways in immunology, oncology, and innate immunity. Its business model combines product sales of research-grade antibodies and cell lines with fee-for-service CRO work in screening, cell line development, and protein production. Founded by Dr. Gita Singh, the company is positioned as a specialized supplier in the large and growing research tools market.

Recombinant antibody (recmAb) and single-domain antibody (sdMAB) platforms for producing research-grade biosimilars and novel binders; expertise in stable/reporter cell line development and protein engineering.

Abeomics competes in the fragmented life science research tools market against giants like Thermo Fisher, Abcam, and Bio-Techne, as well as numerous specialized antibody and CRO companies. Its differentiation lies in its focused recombinant biosimilar platform, single-domain antibody technology, and integrated product-service offering.